Revolution Medicines (RVMD) Return on Capital Employed (2020 - 2026)
Revolution Medicines' quarterly Return on Capital Employed came in at 21.94% in Q1 2026, up 1233.0% year-on-year from 1.65% in Q1 2025, and down 85.9% quarter-over-quarter from 11.8% in Q4 2025.
Revolution Medicines has reported Return on Capital Employed for 7 years, with the latest figure at 21.94% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1233.0% year-over-year to 21.94%; the trailing twelve-month figure through Mar 2026 stood at 21.94% (up 1233.0% YoY), and the FY2025 full-year result was 10.97%, up 2116.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 21.94%, down from 11.8% in the prior quarter.
- The five-year high for Return on Capital Employed was 11.8% in Q4 2025, with the low at 49.5% in Q3 2025.
- Average Return on Capital Employed over 5 years is 33.83%, with a median of 34.27% recorded in 2025.
- Year-over-year, Return on Capital Employed tumbled 1883 bps in 2022 and jumped 2273 bps in 2025.
- Tracing RVMD's Return on Capital Employed over 5 years: stood at 34.12% in 2022, then decreased by 4 bps to 35.33% in 2023, then climbed by 2 bps to 34.53% in 2024, then jumped by 66 bps to 11.8% in 2025, then tumbled by 86 bps to 21.94% in 2026.
- The last three Return on Capital Employed figures came in at 21.94% (Q1 2026), 11.8% (Q4 2025), and 49.5% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -21.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.94% |
| Dec 31, 2025 | -11.80% |
| Sep 30, 2025 | -49.50% |
| Jun 30, 2025 | -40.56% |
| Mar 31, 2025 | -34.27% |
| Dec 31, 2024 | -34.53% |
| Sep 30, 2024 | -39.00% |
| Jun 30, 2024 | -34.27% |
| Mar 31, 2024 | -29.23% |
| Dec 31, 2023 | -35.33% |
| Sep 30, 2023 | -39.10% |
| Jun 30, 2023 | -32.37% |
| Mar 31, 2023 | -31.02% |
| Dec 31, 2022 | -34.12% |
| Sep 30, 2022 | -38.03% |
| Jun 30, 2022 | -38.05% |
| Mar 31, 2022 | -31.94% |
| Dec 31, 2021 | -27.81% |
| Sep 30, 2021 | -24.08% |
| Jun 30, 2021 | -19.22% |
| Mar 31, 2021 | -19.67% |
| Dec 31, 2020 | -20.73% |
| Sep 30, 2020 | -19.95% |
| Jun 30, 2020 | -20.03% |
| Mar 31, 2020 | -21.89% |